Please login to the form below

Not currently logged in
Email:
Password:

Aspen Pharmacare

This page shows the latest Aspen Pharmacare news and features for those working in and with pharma, biotech and healthcare.

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing. Amid reports of price increases of several hundred per cent. ... Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid

Latest news

  • GSK sells another chunk of South Africa's Aspen GSK sells another chunk of South Africa's Aspen

    GSK sells another chunk of South Africa's Aspen. Paid $418m for an 18% share in Aspen in 2009. ... GlaxoSmithKline (GSK) has cashed in part of its holding in South Africa's Aspen Pharmacare, raising cash to help fund the ongoing restructuring of its

  • Publicis boosts South Africa presence Publicis boosts South Africa presence

    The agency has 80 staff and works with blue-chip clients such as Aspen Pharmacare, Tanqueray Gin and TOTAL.

  • GSK cashes in its stake in Africa's Aspen GSK cashes in its stake in Africa's Aspen

    GlaxoSmithKline (GSK) has agreed to reduce its stake in Aspen Pharmacare but says it will maintain a "close relationship" with the South African company. ... Aspen's shares dipped nearly 4 per cent on news of the divestment.

  • GSK sells Lucozade and Ribena for £1.35bn GSK sells Lucozade and Ribena for £1.35bn

    it offloaded several other products to to Aspen Pharmacare for £164m.

  • Pharma deals during August 2012 Pharma deals during August 2012

    As Aspen is the major generic player in Australia this represents a viable generics strategy for GSK in this market. ... 430. GSK / Aspen Pharmacare. Divestment. Divestment of classic brands in Australia.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    840. GSK / Aspen Pharmacare. Acquisition of assets. 2. Arixtra and Fraxiparine - anti-thrombotic agents.

  • Pharma deals during September 2013 Pharma deals during September 2013

    GSK also received $700m from the sale of two thrombosis drugs (Arixtra and Fraxiparine), to Aspen Pharmacare, South Africa's largest drug maker. ... This agreement provides Aspen with the opportunity to expand into Russia and the CIS.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics